This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook MT
Hamilton Thorne Brief: 2024 guidance is for a sales range between US$78 and $82 million representing 10-15% organic growth; Q1 guidance is for a sales range of $19.0 to $19.4 million MT
Hamilton Thorne Brief: Revenue of US$18.4 million for the 4th quarter; And Adj. EBITDA of $3.7 million for the quarter MT
Transcript : Hamilton Thorne Ltd., Q4 2023 Earnings Call, Mar 27, 2024
Hamilton Thorne Ltd. Provides Earnings Guidance for the First Quarter 2024 and Full Twelve Months of 2024 CI
Hamilton Thorne Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
Hamilton Thorne Maintained at Buy at Stifel GMP Ahead of Q4 Results; Price Target Kept at C$2.75 MT
Hamilton Thorne Ltd. Announces Executive Changes, Effective January 15, 2024 CI
Hamilton Thorne Ltd. Announces CEO Changes, Effective January 15, 2024 CI
Hamilton Thorne Q3 Sales increased 16% YoY to US$15.7 Million MT
Hamilton Thorne Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Hamilton Thorne Ltd., Q3 2023 Earnings Call, Nov 13, 2023
Hamilton Thorne Brief: Q3 Sales increased 16% year over year to US$15.7 Million; Net loss was $785,000; After quarter end, Company Completed Aacquisition of Gynetics MT
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms DJ
Hamilton Thorne Ltd. agreed to acquire Gynetics Medical Products N.V. for an enterprise value of ?18.3 million. CI
Chart Hamilton Thorne Ltd.
More charts
Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and consumables to meet customer requirements. Its branded instrument, equipment and software product lines include precision laser devices, imaging systems, incubators, laminar flow workstations, air purification systems, control rate freezers, lab monitoring systems, and micromanipulation systems. It also offers a portfolio of artificial intelligence (AI)-enabled common astronomy software applications (CASA) software and other product offerings. Its GM501 family of products provides the in vitro fertilization (IVF) lab with comprehensive cell culture media solutions.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.001 USD
Average target price
1.665 USD
Spread / Average Target
+66.33%
Consensus
  1. Stock Market
  2. Equities
  3. HTL Stock
  4. News Hamilton Thorne Ltd.
  5. Hamilton Thorne Brief: 2024 guidance is for a sales range between US$78 and $82 million representing 10-15% organic growth; Q1 guidance is for a sales range of $19.0 to $19.4 million